207 related articles for article (PubMed ID: 14504825)
1. NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy.
Neal ZC; Imboden M; Rakhmilevich AL; Kim KM; Hank JA; Surfus J; Dixon JR; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
Cancer Immunol Immunother; 2004 Jan; 53(1):41-52. PubMed ID: 14504825
[TBL] [Abstract][Full Text] [Related]
2. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
Neal ZC; Yang JC; Rakhmilevich AL; Buhtoiarov IN; Lum HE; Imboden M; Hank JA; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
Clin Cancer Res; 2004 Jul; 10(14):4839-47. PubMed ID: 15269160
[TBL] [Abstract][Full Text] [Related]
3. Flt3-L gene therapy enhances immunocytokine-mediated antitumor effects and induces long-term memory.
Neal ZC; Sondel PM; Bates MK; Gillies SD; Herweijer H
Cancer Immunol Immunother; 2007 Nov; 56(11):1765-74. PubMed ID: 17426968
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.
Yang RK; Kalogriopoulos NA; Rakhmilevich AL; Ranheim EA; Seo S; Kim K; Alderson KL; Gan J; Reisfeld RA; Gillies SD; Hank JA; Sondel PM
Cancer Immunol Immunother; 2013 Aug; 62(8):1303-13. PubMed ID: 23661160
[TBL] [Abstract][Full Text] [Related]
5. Combining Immunocytokine and
Bates PD; Rakhmilevich AL; Cho MM; Bouchlaka MN; Rao SL; Hales JM; Orentas RJ; Fry TJ; Gilles SD; Sondel PM; Capitini CM
Front Immunol; 2021; 12():668307. PubMed ID: 34489927
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.
Yang RK; Kalogriopoulos NA; Rakhmilevich AL; Ranheim EA; Seo S; Kim K; Alderson KL; Gan J; Reisfeld RA; Gillies SD; Hank JA; Sondel PM
J Immunol; 2012 Sep; 189(5):2656-64. PubMed ID: 22844125
[TBL] [Abstract][Full Text] [Related]
7. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma.
Aiken TJ; Erbe AK; Zebertavage L; Komjathy D; Feils AS; Rodriguez M; Stuckwisch A; Gillies SD; Morris ZS; Birstler J; Rakhmilevich AL; Sondel PM
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618290
[TBL] [Abstract][Full Text] [Related]
9. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery.
Kowalczyk A; Wierzbicki A; Gil M; Bambach B; Kaneko Y; Rokita H; Repasky E; Fenstermaker R; Brecher M; Ciesielski M; Kozbor D
Cancer Immunol Immunother; 2007 Sep; 56(9):1443-58. PubMed ID: 17597331
[TBL] [Abstract][Full Text] [Related]
10. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.
Lum HD; Buhtoiarov IN; Schmidt BE; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Leukoc Biol; 2006 Jun; 79(6):1181-92. PubMed ID: 16565324
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral immunocytokine treatment results in enhanced antitumor effects.
Johnson EE; Lum HD; Rakhmilevich AL; Schmidt BE; Furlong M; Buhtoiarov IN; Hank JA; Raubitschek A; Colcher D; Reisfeld RA; Gillies SD; Sondel PM
Cancer Immunol Immunother; 2008 Dec; 57(12):1891-902. PubMed ID: 18438664
[TBL] [Abstract][Full Text] [Related]
12. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN
Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365
[TBL] [Abstract][Full Text] [Related]
13. Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer.
Ciavarra RP; Somers KD; Brown RR; Glass WF; Consolvo PJ; Wright GL; Schellhammer PF
Cancer Res; 2000 Apr; 60(8):2081-4. PubMed ID: 10786663
[TBL] [Abstract][Full Text] [Related]
14. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides.
Buhtoiarov IN; Sondel PM; Eickhoff JC; Rakhmilevich AL
Immunology; 2007 Mar; 120(3):412-23. PubMed ID: 17163960
[TBL] [Abstract][Full Text] [Related]
15. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells.
Salcedo R; Stauffer JK; Lincoln E; Back TC; Hixon JA; Hahn C; Shafer-Weaver K; Malyguine A; Kastelein R; Wigginton JM
J Immunol; 2004 Dec; 173(12):7170-82. PubMed ID: 15585838
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma.
Lode HN; Dreier T; Xiang R; Varki NM; Kang AS; Reisfeld RA
Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2475-80. PubMed ID: 9482910
[TBL] [Abstract][Full Text] [Related]
17. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
Morrison BJ; Steel JC; Morris JC
BMC Cancer; 2018 Apr; 18(1):469. PubMed ID: 29699516
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy.
Lode HN; Xiang R; Dreier T; Varki NM; Gillies SD; Reisfeld RA
Blood; 1998 Mar; 91(5):1706-15. PubMed ID: 9473237
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis.
Ma D; Niederkorn JY
Immunology; 1995 Oct; 86(2):263-9. PubMed ID: 7490128
[TBL] [Abstract][Full Text] [Related]
20. Low-dose interferon gamma renders neuroblastoma more susceptible to interleukin-2 immunotherapy.
Sigal RK; Lieberman MD; Reynolds JV; Shou J; Ziegler MM; Daly JM
J Pediatr Surg; 1991 Apr; 26(4):389-95; discussion 395-6. PubMed ID: 1905348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
